The Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services recently announced the . GLIDE aims to develop physical, pharmacologic, gene and cell-based therapeutic interventions to treat primary and rare lymphatic disease (LD) and chronic conditions complicated by lymphatic dysfunction.
GLIDE’s goals are spread across two technical areas for developing new physical and pharmacological therapies targeting abnormal lymphatic structure and function. Through advances in biomaterials, interventional radiology (IR) and minimally invasive surgical approaches and imaging, GLIDE will accelerate therapeutic options in compression, IR, microsurgery, and other minimally invasive technologies. Additionally, GLIDE will support the development of targeted pharmacologic gene and cell therapies that directly target mechanisms of lymphatic dysfunction to modulate tissue contractility and vessel growth.
For more information on the GLIDE program, ARPA-H will host a Sept. 17.
For more information about 黑料网® (黑料网®) collaborations with ARPA-H, contact Katie Grady, 黑料网 Government Affairs Director.